Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Citius Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 30 Sep 2024 to 30 Sep 2025.
Citius Pharmaceuticals, Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 30 Sep 2025 was $224,000, a 234% increase year-over-year.
* An asterisk sign (*) next to the value indicates that the value is likely invalid.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.